Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nonivamide
- Development stage
- Phase 3
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Topical, Oral, Intranasal
01
Overview
Nonivamide, also known as pelargonic acid vanillylamide or PAVA, is a synthetic analog of capsaicin and a capsaicinoid. This small molecule is commonly manufactured synthetically and is utilized in the pharmaceutical industry for its analgesic and anti-inflammatory properties. It is primarily administered topically in creams, ointments, and patches for conditions such as muscle and joint pain, including acute low back pain. Nonivamide's main mechanism involves activating the transient receptor potential vanilloid 1 (TRPV1) receptor, leading to a sensation of heat followed by desensitization and pain relief. Additionally, it has been investigated for its role in preventing dietary-induced body fat gain and its anti-inflammatory effects, which may involve inhibiting the NF-κB/NLRP3 pathway.
- Brand names
- FinalgonZostrix
- Other names
- pelargonic acid vanillylamidenonylic vanillylamideN-[4-hydroxy-3-methoxy-benzyl]nonanamideN-vanillylnonamidenonylic acid vanillyl amidevanillyl pelargonic amidepelargonyl vanillyl amidepseudocapsaicinsynthetic capsaicin
02
Targets
TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on nonivamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nonivamide.